Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FDMT vs ALXO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALXO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–5 Matrix Metrics)

ALXO Overall Winner 6-Pillar Tally: FDMT 2 – 3 ALXO (1 Tie) Matrix Metrics: FDMT 5 – 3 ALXO

As of Nov 16, 2026, ALX Oncology Holdings Inc. (ALXO) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas ALXO carries 61.5/100 (BUY) at $0.95 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ALXO earns the overall head-to-head edge with a stronger Unified Composite Score (61.5/100 BUY vs. FDMT 42.1/100 HOLD) and 1.46β · 117% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile ALXO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FDMT vs ALXO
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $12.12 · SMA50: $13.08
ALXO NASDAQ Head-to-Head Winner
ALX Oncology Holdings Inc. Common Stock
Pharmaceutical Preparations
$0.95
-9.07% 1D
Market Cap $149.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.46β · 117% Vol
Unified Composite Score
61.5 / 100 BUY
Tech 50.0 Fund 60.0 Flow 68.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.9%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $1.18 · SMA50: $1.33

6-Pillar Scorecard Institutional Category Breakdown (FDMT 2 – 3 ALXO)

Columns: Metric · FDMT · ALXO
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.6x N/M
2. Growth & Scale FDMT
Revenue Growth (YoY) +4505.6% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M N/A
Market Cap $669.3M $149.3M
3. Profitability & Quality ALXO
Gross Margin N/A N/A
Operating Margin -222.7% 0.0%
Net Profit Margin -208.6% 0.0%
Return on Equity (ROE) -56.7% -80.7%
4. Balance Sheet & Cash Flow ALXO
Cash Generation (TTM) -$156M -$71M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Cash $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALXO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 82.4% (10th %ile) 146.2% (20th %ile)
Put/Call OI Skew 5.16x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FDMT (5) vs ALXO (3)
Institutional Metric FDMT ALXO Criterion Row Edge
Market Capitalization
Scale
$669.3M $149.3M Larger Scale FDMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+4505.6% -100.0% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-222.7% 0.0% Higher Margin ALXO
Net Profit Margin
Profitability
-208.6% 0.0% Higher Margin ALXO
Return on Equity (ROE)
Capital Efficiency
-56.7% -80.7% Higher ROE FDMT
52-Week Range Position
Momentum
47% ($7–$17) 5% ($1–$3) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.89β · 90% Vol 1.46β · 117% Vol Lower Realized Risk FDMT
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 61.5 / 100 (BUY) Higher Composite ALXO
Trailing 12M Revenue (USD)
Operating Scale
$96M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$156M ($31M Net Cash) -$71M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +6.74 pp
FDMT: -4.04% · ALXO: -10.78%
3M Horizon FDMT +33.67 pp
FDMT: -20.86% · ALXO: -54.53%
6M Horizon FDMT +91.99 pp
FDMT: +39.27% · ALXO: -52.72%
1Y Horizon FDMT +35.81 pp
FDMT: +13.33% · ALXO: -22.48%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FDMT Revenue ALXO Revenue FDMT Op. Margin ALXO Op. Margin Margin Leader
FY2018 N/A $0M N/A -662.0% ALXO
FY2019 $10M $0M -729.4% -400.0% ALXO
FY2020 $10M $0M -424.0% -3694.0% FDMT
FY2021 $20M N/A -395.5% N/A FDMT
FY2022 $0M N/A -3516.5% N/A FDMT
FY2023 $20M N/A -544.6% N/A FDMT
FY2024 $0M N/A -507678.4% N/A FDMT
FY2025 $90M N/A -187.2% N/A FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALXO BREAKDOWN
93d in phase · OBV NEUTRAL
Current IV 146.2%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ALXO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ALXO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $149.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FDMT vs ALXO Key Questions & Quantitative Answers

As of Nov 16, 2026, ALX Oncology Holdings Inc. (ALXO) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas ALXO carries 61.5/100 (BUY) at $0.95 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ALXO earns the overall head-to-head edge with a stronger Unified Composite Score (61.5/100 BUY vs. FDMT 42.1/100 HOLD) and 1.46β · 117% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile ALXO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with ALXO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FDMT cumulative revenue shifted +800.0% while ALXO shifted N/A. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ALXO.

FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas ALXO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus ALXO (-80.7% ROE) capital efficiency.

In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, ALXO carries 146.2% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 117% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.